Medical network - January 5, 2016, investments and acquisitions very frequently, often never even had countless billions of transactions, these all reflect the medical industry is in a stage of development.
Back in 2016 YiXie industry and investment circle big events.
On January 8, 2016
Hammer flew by more than 50% market value to acquire global best gene chip company
Game's fly the world's science and technology corporation (Thermo Fisher) announced that agreed by the board of directors of the company, for the price of $14 per share in cash, total amount is $1.3 billion buying famous chipmaker aung flying chips (Affymetrix, also have translation ivy matrix). The acquisition will strengthen the vision to fly the world's leading status in the biological sciences, and provide a new clinical research opportunities in the field of genetic and application market. Affymetrix USES cells products will help the company develop the market, also with the help of the global business contact of fly, these products will serve more customers.
On February 2, 2016
Stryker SageProducts $2.78 billion
Stryker corp. announced in the form of a total $2.78 billion in cash from MADIson Dearborn Partners to buy SaGEProducts, aimed at strengthening for more patients to provide a full range of medical services. Takeover Sage company to provide oral health care, skin regeneration and protection, clean patient care, installation and orientation of foot service of medical equipment, etc. The two companies in the production of products completely complementary, particularly in the field of much-needed infection division.
On February 16, 2016
Stryker will be $1.28 billion deal to buy defibrillator manufacturer
Famous American orthopedic medical company Stryker corp. announced that it will for $1.28 billion in cash from private equity firm Bain Capital, Bain Capital acquisition defibrillator manufacturer Physio - Control International company (Physio - Control International, Inc.). At the beginning of the second quarter is expected to complete the transaction, and will help the Stryker's earnings growth.
On March 6, 2016
Mindray announced privatization, the company from the nyse
In the United States listed on the nyse member of China Medical apparatus and instruments of Mindray Medical (Mindray Medical International) announced that it has been completed privatisation deals worth $3.3 billion. This $28 a share deal means that mindray medical in nyse trading shares MR ended.
On March 8, 2016
Canon, Toshiba medical system, a subsidiary of the winning $6.2 billion offer
Canon company beat Japan Fuji film company, and eventually bought for $6.2 billion subsidiary Toshiba medical system. Toshiba medical systems for Toshiba quality subsidiary, mainly engaged in magnetic resonance imaging (MRI), X-ray tester and other medical equipment manufacturing sales. For the acquisition of Toshiba medical systems, Canon said in the future will make full use of Toshiba medical image diagnosis technology, strengthen medical business, will also aim to develop relevant new areas, to explore further acquisitions.
In March 2016,
Johnson's $55 million acquisition of NeuWave medical equipment company
Johnson & Johnson announced that it will NeuWave company, $55 million deal to buy medical equipment developers used to get the latter development of soft tissue microwave ablation. And now the technology is in the half of the top cancer treatment center has gained popularity.
On April 28, 2016
Abbott laboratories' $25 billion acquisition of st Jude and big
Abbott pharmaceutical company announced it had agreed to about $25 billion for Medical equipment manufacturer St Jude Medical company (st. Jude Medical), to strengthen the heart and nervous system equipment business. Abbott size matches the Johnson & Johnson after the merger, health and beauty.
In April 2016,
Siemens medical announced acquisition of molecular diagnostics company NEO
Siemens announced the acquisition of NEO NewOncology AG. The diagnosis of abnormal development and sales of molecular diagnosis platform NEO, it provides the choice of targeted therapy for cancer patients, physicians of decision support. Thanks to this, Siemens Healthineers for tumor molecular diagnosis can dig and more rapid growth.
On May 18, 2016
Smith & $350 million sale of department of gynaecology to medtronic medical technology
British & medical company (Smith & Nephew) announced that will sell its medical technology business of department of gynaecology to Medtronic (Medtronic), priced at $350 million.
On June 7, 2016
ZimmerBiomet LDR Holding $1 billion
Zimmer Biomet announced acquisition of focus for spinal surgery process development of innovative technology, a French company LDRHolding, to enhance their business innovation and growth of the spine, deal worth about $1 billion.
On June 14, 2016
Weigao orthopaedic 6 billion, backdoor listings a-shares
A-share listed company Henderson daxin announcement, in all their assets and liabilities and shandong weigao orthopedic material co., LTD., the equivalent part for replacement. Henderson daxin buy the assets of 1.219 billion yuan, weigao orthopaedic 100% stake for 6.06 billion yuan.
On July 5, 2016
The world's first biological absorbable stent local time, the United States approved listing!
The FDA announced the approval of abbott Absorb GT1 biodegradable absorption heart stents system on the market. According to abbott products page, this is also the world's first fully absorbed by the body of the stent.
In July 2016,
Zimmer Biomet to buy the French novel surgical robot system developers
Focus on cross-border medical investment funds remitted bridge capital group, announced the global headquarters is located in the United States indiana orthopaedic giant Zimmer Biomet Holdings, Inc., a sale of its Holdings of Medtech SA's rights and interests. MedtechSA headquartered in France is a new type of surgery robot system developers, is currently in the pan-european stock exchange. The company's flagship product including Brain surgery robot (" ROSA "Brian") and spinal minimally invasive surgery robot (" ROSASpine "). After the completion of the acquisition Zimmer Biomet will, through its strong global network and resources to help Medtech of minimally invasive surgery robot to benefit more neurologist and orthopaedic patients around the world. "
On August 18, 2016
The fly rumors to acquire illumina
Game's fly the world's science and technology (Thermo Fisher Scientific) announced a proposed $30 billion takeover of the leading enterprises in the global gene sequencing machine illumina.
On September 1, 2016
Nestle layout medical: $130 million acquisition of medical equipment company
Nestle announced the acquisition of British medical device company Phagenesis message. Phagenesis focus on the innovation of dysphagia therapy. Phagenesis was founded in 2007, the company boasts its own therapy, rather than just treats the symptoms. Company President Reinhard Krickl said in an interview, through the traditional method of speech therapy for weeks or even months to work, and the revolutionary new Phagenesis therapy only need a few days. Nestle's investment will accelerate the development of Phagenyx.
On September 5, 2016
Cepheid Danaher40 $to buy molecular diagnostics company
American industry and medical equipment manufacturers danner Hector (Danaher) group announced that has agreed to a $4 billion (including debt) acquisition of Cepheid silicon valley high-tech molecular diagnostics company. Is a innovative molecular diagnostic product supplier, Cepheid provides from the bed testing (POCT) to go to the hospital center laboratory can be used to molecular diagnosis of form a complete set of equipment and consumables, has covered a variety of infectious diseases and tumor detection solution.
On September 14, 2016
66 billion dollars! Germany's bayer acquisition monsanto!
German bayer pharmaceutical and agrochemical company announced that it will for the price of $128 a share for the monsanto, trading at $66 billion. Bayer said that the deal has been monsanto's board of directors, bayer management committee and bayer's consistent approval of the board of supervisors, the future still need to get the monsanto the consent of the shareholders' meeting and national regulators. The transaction is expected to be completed by the end of 2017.
On September 17, 2016
Johnson & Johnson group's $4.3 billion takeover of abbott eye operations
American pharmaceutical giant Johnson &johnson, Johnson & Johnson company announced it would $4.3 billion buying American pharmaceutical company Abbott Medical called. The company is the wholly owned subsidiary of the American institute of AbbottLaboratories before. Abbott Medical called principal business is the eye and eye surgery technology.
In September 2016,
Look at Johnson & Johnson did what great things over the years
Johnson & Johnson has become the world's largest, most comprehensive, the most popular business distribution of health care enterprise, business related to consumer, pharmaceutical, medical equipment three areas. Through the integration of mergers and acquisitions in recent years, medical incubator, intelligent medical, mobile medical treatment, medical data, YiXie to strategic layout, pharmaceutical industry, etc. At present, Johnson & Johnson family owns the world's sixth largest consumer goods company, the world's most comprehensive medical equipment company, the world's sixth largest biotechnology company, the world's fifth-largest pharmaceuticals company, headquartered in New Jersey, new buren zwick, more than 60 countries around the world with more than 265 subsidiaries, nearly 126500 employees.
On October 18, 2016
Abbott laboratories and st Jude will sell $1.1 billion of vascular closure and electrophysiological business to terumo manufacturers
Abbott Abbott Laboratories (NYSE: ABT) and st Jude medical care
St JudeMedical (NYSE: STJ) announced that once complete acquisition of St Jude abbott, mergers will be $1.1 billion bits of the vascular closure and electrophysiology business to Terumo Corp. This agreement including st Jude's Angio - Seal and Femoseal products, and abbott's Vado Steerable Sheath.
In November 2016,
Novartis chairman said considering selling alcon
Novartis, chairman of the board of Joerg Reinhardt said in an interview with Swiss media, alcon in the past two years of development is not in line with expectations, from a long-term perspective, considering selling it. May, novartis announced the pharmaceutical business spin-off for two business units. At this point, novartis's new architecture is divided into the innovation medicine division, sanders, and three large alcon. If the future novartis really cross the rubicon selling alcon, short of a full strategic framework and how to make up for it?
On November 8, 2016
Step length pharmaceutical secondary IPO success eventually, more than 40 institutions share capital appreciation
Step length pharmaceutical industry start online and offline issue purchase; On November 18, step length pharmaceutical officially listed in the Shanghai stock exchange transactions, opened in a single share 67.07 yuan, at 80.47 yuan/and quickly harden, applies to 44.01%. After step pharmaceutical market, with its revenue and profit levels, will enter into the class of traditional Chinese medicine the first echelon of listed companies.
On December 19, 2016
Minimally invasive medical again, investment artery coated stents
Minimally invasive Medical (HK0853) and shares listed Medical devices company Lombard, Medical, Inc. (NASDAQ: EVAR) announced that the two sides reached a strategic cooperation and minimally invasive? Medical to Lombard Medical injection protocol. Lombard Medical focus on the aorta intracavitary repair Medical equipment company. With minimally invasive Medical and Lombard Medical in patients with aortic vascular lumen and rich product line, the cooperation will develop the Chinese market the most comprehensive treatment of abdominal aortic aneurysm cavity of product lines, to further consolidate the minimally invasive Medical in the rapid development of China's aorta vascular lumen intervention in the market leading position, and help the minimally invasive? Medical international aortic vascular cavity in a market with enormous potential in future in the market. |
